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Background: The mechanism by which Rab GTPases and their effectors act in tethering is not well understood.
Results: An in vitro assay was developed to study vesicle clustering by the Lgl family member Sro7.
Conclusion: Clustering in vitro and in vivo depends on the conformation of the Rab GTPase and Sro7.
Significance: This assay provides a new tool to dissect the role of Rab and Lgl family function.
Intracellular traffic in yeast between the Golgi and the cell
surface is mediated by vesicular carriers that tether and fuse in a
fashion that depends on the function of the Rab GTPase, Sec4.
Overexpression of either of two Sec4 effectors, Sro7 or Sec15,
results in the formation of a cluster of post-Golgi vesicles within
the cell. Here, we describe a novel assay that recapitulates post-
Golgi vesicle clustering in vitro utilizing purified Sro7 and vesi-
cles isolated from late secretory mutants. We show clustering in
vitro closely replicates the in vivo clustering process as it is
highly dependent on both Sro7 and GTP-Sec4. We also make
use of this assay to characterize a novel mutant form of Sro7 that
results in a protein that is specifically defective in vesicle clus-
tering both in vivo and in vitro. We show that this mutation acts
by effecting a conformational change in Sro7 from the closed to
a more open structure. Our analysis demonstrates that the
N-terminal propeller needs to be able to engage the C-terminal
tail for vesicle clustering to occur. Consistent with this, we show
that occupancy of the N terminus of Sro7 by the t-SNARE Sec9,
which results in the open conformation of Sro7, also acts to
inhibit vesicle cluster formation by Sro7. This suggests a model
by which a conformational switch in Sro7 acts to coordinate
Rab-mediated vesicle tethering with SNARE assembly by
requiring a single conformational state for both of these pro-
cesses to occur.
We identified Sro7, the yeast member of the conserved fam-
ily of Lgl proteins, in a screen for binding partners of the plasma
membrane t-SNARE Sec9 (1). Loss of Sro7 and its redundant
paralog Sro77 results in both cold-sensitive growth and a severe
secretory defect in post-Golgi vesicle tethering/fusion with the
plasma membrane (1). Importantly, Sro7 has been suggested to
function as a direct effector of the GTPase Sec4 in a pathway
that genetically appears to be parallel to that of the other effec-
tor of Sec4, the exocyst tethering complex (2). Although Sro7
has been found to interact with several components of the exo-
cytic tethering and fusion apparatus (1, 3, 4), the precise molec-
ular mechanism by which it functions in this process remains
elusive. Structural analysis has shown that Sro7 is composed of
two interlocking -propellers with a long C-terminal tail that
binds back to the N-terminal propeller in an autoinhibitory
mode. The region bound by the tail was shown to overlap with
the binding site of the plasma membrane t-SNARE Sec9 in a
way that suggested the possibility of a “triggered” release of the
SNARE by Sro7 (5). Although the Sec4 GTPase remained an
attractive candidate triggering factor, its association with Sro7
had previously been shown to have no effect on Sro7’s associa-
tion with Sec9 (2). Therefore, the precise role of Sro7 as an
effector of the Rab GTPase Sec4 remains elusive.
Overexpression of Sro7 in the cell results in the accumula-
tion of a large cluster of post-Golgi vesicles and cell lethality (4).
This observation was similar to that seen for another effector of
the Sec4 GTPase, the Sec15 subunit of the exocyst tethering
complex (6). In vivo analysis of the vesicle clustering phenotype
showed that clustering and cell lethality by both Sec15 and Sro7
depend on Sec4 function but are independent of the Sec9
t-SNARE (4, 6). In the case of Sro7, vesicle clustering also
depends upon the interaction between Sro7 and the type V
myosin Myo2 (4).
In this study, we establish an in vitro assay that recapitulates
the Sro7-mediated clustering we observed previously in vivo.
Development of such an assay allows us to begin to biochemi-
cally dissect Rab GTPase and Rab effector function in parallel to
our in vivo genetic analyses. We made use of this assay to ana-
lyze the effects of Sro7 mutants in which conserved charged
patches on Sro7 were mutated to the reverse charge. We found
that one of the charge reversal mutant proteins, Sro7-
R189D,R222D, had a specific defect in clustering vesicles both
in vivo and in vitro. Further analysis of this defect demonstrated
a role for the “closed” conformation of the C-terminal autoin-
hibitory tail in vesicle clustering. This suggests a novel function
for the conformational switch in Sro7 in coordinating Rab-de-
pendent membrane tethering with regulation of SNARE assem-
bly prior to membrane fusion.
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EXPERIMENTAL PROCEDURES
Plasmids Used—Single copy plasmids expressing Sro7 or
charge reversal point mutations were obtained by site-directed
mutagenesis on pB741 (SRO7,CEN, and HIS3). All GAL-SRO7
constructs, previously subcloned into the integrating vector
pB24 (LEU2) as BamHI-HindIII fragments, were then sub-
cloned as BamHI-ApaI inserts into pB38 (GAL, CEN, and
HIS3). Protein A-tagged Sro7 constructs were generated as
BamHI-HindIII fragments in pB966 (2, URA3, plasmid con-
taining the ADH1 promoter and a protein A tobacco etch virus
tag). Full-length Sec9 with an N-terminal GST tag and a C-termi-
nal His6 tag was obtained as described previously (7). Soluble GST-
Snc1, GST-Sso1, and GST-Sso1(193–265) were obtained by
standard glutathione elution of the fusion protein from glutathi-
one-Sepharose beads following the manufacturer’s directions (GE
Healthcare). Plasmid for recombinant GDI2 production, pGDI-
CBD, was a gift of V. Starai and was used as described (8).
Protein Purification—Sro7 with an N-terminal Protein A tag
was obtained from a modification of the purification protocol
described previously (2). Sro7 was expressed behind an ADH1
promoter from a high copy plasmid in a yeast pep4 back-
ground strain. Approximately 5 liters of cells were grown over-
night in synthetic media to an A599 of 3.0 and then shifted to
YP  2% glucose for one doubling time. Cells were then harvested
and washed in 200 ml of ice-cold buffer containing 10 mM Tris,
pH 7.8, 20 mM sodium azide, and 20 mM sodium fluoride to
yield a final wet weight of 50 g of cells. Cells were frozen on
dry ice and stored at 80 °C. Lysis was obtained with a bead
beater using ice-cold buffer containing 20 mM Tris, pH 7.8, 150
mM NaCl, 0.5% Tween 20, and 1 mM DTT, and protease inhib-
itors (2 g/ml leupeptin, 2 g/ml aprotinin, 2 g/ml antipain,
14 g/ml pepstatin A, and 1 mM phenylmethylsulfonyl fluo-
ride). Five cycles of 1-min bead beating, followed by 2-min
intervals on ice were used to lyse the cells. The lysate (60 ml)
was then spun at 17,400  g for 10 min at 4 °C in a JA 25.5 rotor
before further dilution (120 ml) and ultracentrifugation at
140,000  g for 30 min at 4 °C in a type 45Ti rotor to yield a final
protein concentration of about 25 mg/ml. Binding to Sepharose
CL-6B beads (1 ml of beads/45 ml of lysate) for 1 h at 4 °C was
then used to preclear the lysate before binding to 1 ml of IgG-
Sepharose beads for 2 h at 4 °C. Beads were then washed five
times with lysis buffer, three times with lysis buffer containing
400 mM NaCl, and three times with ice-cold cleavage buffer
containing 20 mM Tris, pH 7.8, 150 mM NaCl, 0.1 mM EDTA,
and 1 mM DTT. Beads were then resuspended 1:1 in cleavage
buffer, and cleavage was obtained with tobacco etch virus cleav-
age enzyme for 5 h at 17 °C (5000 units of tobacco etch virus/
3-ml bed volume beads). Supernatant containing the cleaved
protein was then collected and frozen at 80 °C.
Vesicle Enrichment—Yeast mutant cells grown overnight in
YP  2% glucose to an A599 of 0.6 were shifted to the restrictive
temperature of 37 °C for 2 h. Sodium azide was then added
(final 20 mM) to the culture, and 300 absorbance units were
centrifuged, washed with 10 ml of 10 mM Tris, pH 7.5, 20 mM
NaN3, and spheroplasted in 10 ml of spheroplast buffer (0.1 M
Tris, pH 7.5, 1.2 M sorbitol, 10 mM NaN3, 21 mM -mercapto-
ethanol, and 0.05 mg/ml Zymolyase 100T) for 30 min at 37 °C.
Spheroplasts were then lysed in 4 ml of ice-cold lysis buffer (10
mM triethanolamine, pH 7.2, 0.8 M sorbitol) with protease
inhibitors (2 g/ml leupeptin, 2 g/ml aprotinin, 2 g/ml anti-
pain, 14 g/ml pepstatin A, and 1 mM phenylmethylsulfonyl
fluoride). The yeast lysate was then centrifuged at 450  g for 4
min at 4 °C to remove unbroken cells, and the remaining lysate
was spun at 30,000  g for 15 min at 4 °C in a Sorvall centrifuge
to pre-clear larger membranes. Approximately 2.5 ml of super-
natant was then labeled with FM4-64 (1 g/ml) for 10 min on
ice. The labeled lysate was then layered over 2 ml of an ice-cold
sorbitol cushion (20% w/v sorbitol in 10 mM triethanolamine,
pH 7.2) and centrifuged at 100,000  g for 1 h at 4 °C. After
removal of the supernatant fraction, the pellet fraction was
resuspended in 600 l of lysis buffer and kept on ice for use in
the clustering assay. When the sec4-8 secretory mutant was
used the following adjustments were made: 600 absorbance
units were harvested and spheroplasted in 15 ml of spheroplast
buffer. The final 100,000  g pellet fraction was resuspended in
700 l of lysis buffer. To obtain an enriched vesicle fraction
from the sec6-4 mutant expressing GFP-Sec4 (CEN), cells
grown overnight in selective media were first shifted to YP 
2% glucose at 25 °C for 1 h before placing them at the restrictive
temperature of 36 °C for 2 h. 350 absorbance units were sphero-
plasted with 10 ml of spheroplast buffer and treated as above
except the 100,000  g pellet was resuspended in 350 l of lysis
buffer. To obtain an enriched vesicle fraction from the snc1;
snc2 GAL-depletion strain, where the sole source of Snc1 is
under the control of the GAL1/10 promoter, cells were grown
in YP  2% glucose and then shifted to YP  3% raffinose for
14 h before harvesting 700 absorbance units that were then
spheroplasted, lysed, and subjected to centrifugation as
described for the sec6-4 mutant strain. The final high speed
pellet fraction was resuspended in 160 l of lysis buffer.
Vesicle Purification—To obtain a homogeneous population
of post-Golgi vesicles, the 100,000  g pellet, obtained as
described above in the vesicle enrichment section, was sub-
jected to a 20 – 40% sorbitol velocity gradient (9). Adjustments
to the above protocol included harvesting 700 absorbance units
of cells and resuspending the 100,000  g pellet in a final vol-
ume of 600 l prior to loading at the top of 11 ml of linear
sorbitol gradient prepared with 1.22-ml steps of 40, 37.5, 35,
32.5, 30, 27.5, 25, 22.5, and 20% sorbitol (w/v) in 10 mM trieth-
anolamine acetate, pH 7.2. The gradient was centrifuged at
71,000  g for 80 min at 4 °C and then fractionated into 0.72-l
fractions. Fractions 5–7 (pink color) containing the vesicle frac-
tions were then pooled, diluted with 3 ml of lysis buffer, and
centrifuged at 100,000  g for 1 h. The pellet fraction contain-
ing the purified vesicles was resuspended in 200 l of lysis
buffer. For vesicle purification from the sec4-8 mutant strain,
the above protocol was adjusted by using 1000 absorbance units
of mutant cells and spheroplasting with 25 ml of spheroplast
buffer. The spheroplasts were then lysed with the same volume
(9 ml) as the sec6-4 mutant cells, and the 100,000  g pellet was
resuspended in 600 l and loaded on a 20 – 40% sorbitol veloc-
ity gradient as described above. The sample was treated identi-
2 The abbreviations used are: GDI, GDP dissociation inhibitor; HSP, high speed
pellet; GTPS, guanosine 5-3-O-(thio)triphosphate; TRITC, tetramethyl-
rhodamine isothiocyanate.
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cally to the sec6-4 mutant strain for the final concentration of
the purified vesicle fraction.
GDI Extraction and Vesicle Purification—For the GDI-
treated vesicles, the following modifications were made to the
vesicle enrichment protocol described above: 1400 absorbance
units of a sec6-4 mutant strain were grown overnight and
shifted to the restrictive temperature of 37 °C for 2 h. The final
high speed pellet fraction was resuspended into 1 ml of lysis
buffer and treated with 0.5 mM GDP and 3.6 mM MgCl2 for 30
min on ice. The vesicles were then split into two 500-l aliquots
that were treated with 8 mM GDI or mock-treated with buffer
only for 30 additional min on ice. Lysis buffer was then added to
bring each volume to 600 l before loading onto two separate
but identical 20 – 40% sorbitol velocity gradients for vesicle
purification. Vesicle-containing fractions from each gradient
were then pooled, concentrated by a high speed centrifugation
at 100,000  g as described in the vesicle purification protocol,
and resuspended in a final volume of 150 l before using in the
in vitro clustering assay.
Antibody Inhibition of Vesicle Clustering in Vitro—For the
antibody inhibition studies, a, HSP fraction obtained from a
sec6-4 mutant strain was incubated with equal amounts of
monoclonal anti-Sec4 or control monoclonal anti-Myc for 1 h
on ice before treating with MgCl2 (3 mM) and nucleotide (1 mM)
for 30 additional min on ice. The vesicles were then incubated
with Sro7 (1 M) for 20 min at 27 °C.
Clustering Assay—Vesicle-enriched fraction or purified ves-
icles (10 l) were preincubated with MgCl2 (3 mM) and nucle-
otide (1 mM) for 30 min on ice prior to addition of Sro7 (1 M)
or mock buffer for 20 min at 27 °C.
Negative Staining—The carbon film grids were glow-dis-
charged in a Harric Plasma Cleaner for 1.5 min. A drop of sample
(10 l) was placed onto a grid that was suspended in reverse for-
ceps for 1 min. The sample was then washed off with 5 drops of 1%
aqueous uranyl acetate. The stain was allowed to sit on the grid for
1 min. The grid was blotted on the tip of the forceps with filter
paper before air drying and was examined by electron microscopy.
Immunofluorescence—Strains containing a CEN vector (pB38)
expressing wild type SRO7, sro7-R189D,R222D, or sro7-
K914,F942 from a GAL-inducible promoter were grown over-
night in synthetic media with raffinose (3%) to early log phase
and then induced with 1% galactose for 6 h before fixing and
processing as described previously (10).
Binding Assays—Bindings of wild type Sro7 or point mutant
forms of Sro7 were set up as described previously (7) for Sec9-
Qbc, Exo84-NT (amino acids 3– 400), and Myo2-IQ (amino
acids 782–990). Bindings to GTP-Sec4 made use of procedures
described in Ref. 2. To compare wild type Sro7 to point mutant
forms of Sro7, two different sets of soluble protein concentra-
tions were used to ensure the binding response was in a linear
range. Student’s t test was done on three individual bindings for
each protein concentration used.
RESULTS
Sro7-dependent Vesicle Clustering in Vitro Requires Magne-
sium Chloride and Is Potentiated by GTPS—We have previ-
ously shown that overexpression of SRO7 behind a GAL1/10
promoter results in a pronounced growth defect and the forma-
tion of a large cluster of post-Golgi vesicles within the cell (4).
Importantly, this clustering is dependent on GTP-Sec4 as
mutations in SEC4 and the gene encoding its exchange factor
SEC2 prevent clustering of vesicles when Sro7 is overexpressed
(4, 11). To further explore how Sro7 mediates vesicle clustering,
we sought to determine whether we could recapitulate this
process in vitro utilizing isolated post-Golgi vesicles and puri-
fied Sro7 protein. Sro7 was purified from yeast by a modifica-
tion of a previous protocol used in the laboratory (2), and post-
Golgi secretory vesicles were isolated from a sec6-4 mutant
strain that accumulates a large number of vesicles following a
shift to the restricted temperature of 37 °C (12, 13). To visualize
vesicles in the assay, they were fluorescently labeled by two
methods. In the first method, vesicles were labeled in vivo by
expression of GFP-Sec4 in a sec6-4 strain, and Sec4 is a well
recognized marker of post-Golgi secretory vesicles (14). In the
second method, vesicles were labeled in vitro with the lipid dye
FM4-64 during the vesicle isolation procedure. In both cases,
post-Golgi vesicles were isolated by cell fractionation following
a shift of the mutant sec6-4 strain to the restrictive temperature.
To determine whether we could reconstitute Sro7-mediated
vesicle clustering in vitro, fluorescently labeled vesicle fractions
were incubated with increasing amounts of purified Sro7 under
a number of different conditions. Following a 20-min incuba-
tion at room temperature, an aliquot of each condition was
analyzed by fluorescence microscopy. Clustering appeared as
the formation of fluorescently labeled puncta that were
observed using either FITC (GFP-Sec4-labeled vesicles) or
TRITC (for FM4-64 labeled vesicles) filter sets. Note individual
post-Golgi vesicles (80 –100 nm) were too small to be visualized
by conventional fluorescence microscopy. When purified Sro7
was added to vesicles in buffer containing GTPS and magne-
sium, large puncta formed that were visible by both FITC and
TRITC channels (Fig. 1A). The appearance of large puncta
depended on the presence of Sro7, magnesium, and GTPS. In
the absence of either magnesium or Sro7, no puncta formed.
Similarly, when BSA or IgG was added in place of Sro7 (at
equivalent amounts), no clustering was observed (data not
shown). When Sro7 and magnesium were present with GDP in
place of GTPS or no added nucleotide was present, then only
small puncta formed (Fig. 1A). Finally, we found that the clus-
tering was dependent on both time and the dose of Sro7, as the
size of puncta increased with time and with increasing amounts
of Sro7 added (data not shown). Routine assays were done with
the addition of Sro7 to 1 M incubated with vesicles for 20 min
at 27 °C. Clustering activity was quantitated by counting the
number of small (greater than 1 m but less than 2 m) and
larger (2 m) clusters formed per 1 l of assay mix (Fig. 1B).
GTP-bound Sec4 Is Required for Sro7-mediated Vesicle Clus-
tering in Vitro—To determine whether the in vitro clustering
was also dependent on Sec4, we prepared FM4-64 labeled
secretory vesicles from a number of late secretory mutants
(sec6-4, sec4-8, sec1-1, and sec9-4) and examined the ability of
purified Sro7 to induce vesicle clustering under the conditions
described above. To ensure we had similar numbers of vesicles
present from each mutant strain, we used immunoblots of the
vesicle fractions used in this assay to monitor levels of three
vesicle markers Sec4, the v-SNARE, Snc1/2, and the t-SNARE,
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Sso1/2 (which transits to the plasma membrane on post-Golgi
vesicles). As expected, the vesicles from sec4-8 have only a small
amount of a form of Sec4 with altered mobility on SDS-PAGE
(14) but have similar amounts of Snc1/2 and Sso1/2 when com-
pared with the other three mutants (Fig. 1D). When these four
vesicle preparations were incubated with Sro7 under the con-
ditions described above, robust clustering was observed for
sec6-4, sec1-1, and sec9-4 vesicle fractions, but only low levels of
small puncta were observed for the sec4-8 vesicle fraction (Fig.
1C). The clustering activity of Sro7 was dose-dependent (Fig.
1E). Therefore, similar to the in vivo clustering, the in vitro
clustering reaction was dramatically impeded with otherwise
equivalent vesicles isolated from a sec4-8 mutant strain.
To further rule out a role for SNARE proteins in Sro7-medi-
ated vesicle clustering, we prepared vesicles from strains defi-
cient in either Snc1/2 or Sso1/2 (15, 16). Using post-Golgi ves-
icles isolated from a strain where the sole source of Snc1 was
under control of the GAL1/10 promoter, we found that cluster-
-Sro7
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FIGURE 1. In vitro system for clustering post-Golgi vesicles in the presence of Sro7, MgCl2, and GTPS. A, sec6-4 mutant strain expressing GFP-Sec4 (CEN)
was shifted to the restrictive temperature of 37 °C to accumulate post-Golgi vesicles. The mutant cells were then spheroplasted, lysed, and spun at 30,000 
g to remove large membranes. The supernatant was then labeled with FM4-64 and spun at 100,000  g over a sorbitol cushion to generate a concentrated HSP
fraction enriched in post-Golgi secretory vesicles. The HSP fraction was then treated with or without MgCl2 (3 mM), GTPS, or GDP (1 mM) for 30 min on ice, and
then Sro7 (1 M) was added for 20 min at 27 °C. A 1-l aliquot of the reaction mixture was analyzed by fluorescence microscopy, and quantitation of vesicle
cluster formation (B) was based on counting 10 images at 60 magnification and separating vesicle clusters by size. Scale bar, 2 m. C, post-Golgi vesicle
fractions (HSP) labeled with FM4-64 were obtained as above from WT, sec6-4, sec4-8, sec1-1, and sec9-4 mutant strains. HSP fractions from the different strains
were then treated with MgCl2 (3 mM) and GTPS (1 mM) for 30 min on ice and then with Sro7 (1 M) for 20 min at 27 °C. D, total vesicle material (HSP) was
monitored by Western blot analysis with vesicle marker proteins (Sec4, Snc1/2, and Sso1/2), and quantitation of in vitro clustering was obtained as in A. Scale
bar, 2 m. E, vesicle clustering in a sec6-4 HSP fraction labeled with FM4-64 increased with the concentration of Sro7 used in the assay.
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ing activity was unaffected, although the amounts of Snc1 on
the vesicles were virtually undetectable (Fig. 2A). Likewise,
when vesicles were isolated from the temperature-sensitive
sso1,sso2-1 strain, we found Sro7-mediated clustering to be
indistinguishable from that seen with vesicles from a sec6-4
strain (Fig. 2B). Taken together with the results from the sec9-4
strain, it is clear that post-Golgi SNARE function was not
required for Sro7-mediated vesicle clustering.
The assay described above makes use of a high speed pellet
fraction produced from differential centrifugation as a highly
enriched source of post-Golgi vesicles (13). To determine
whether purified post-Golgi vesicles are active in Sro7-medi-
ated clustering, we subjected the FM4-64-labeled vesicle-en-
riched fraction to velocity sedimentation on sorbitol gradients
(9). Vesicle purification was performed in parallel on both
sec6-4 and sec4-8 mutant strains and examined under condi-
tions identical to those described above, except that clustering
reactions were allowed to incubate for 60 rather than 20 min to
achieve similar levels of clustering as monitored by fluores-
cence microscopy (Fig. 3, A and B). The use of velocity gradient-
purified vesicles of homogeneous size also allowed us to
examine the clustering reactions by negative stain electron
microscopy. The results, shown in Fig. 3C, demonstrate that
Sro7 induces clustering, but not fusion, of purified 80 –100-nm
post-Golgi vesicles and that this clustering depends on both
GTPS and Sec4 function. Both Western blot quantitation of
Snc1/2 levels and negative stain analysis of the purified vesicles
demonstrate that equivalent numbers of sec6-4 and sec4-8 ves-
icles were used in this analysis (Fig. 3, C and D). Importantly, the
quantification of vesicle clustering observed by electron
microscopy is remarkably similar to the data obtained by quan-
tification of the clustering reaction by fluorescence microscopy,
indicating that both methods of visualizing clustering are
indeed measuring the same event.
The Sec4 GTPase can cycle on and off membranes in a man-
ner that is dependent on the nucleotide state of the Rab and its
interaction with GDI (17). To determine whether the absence
of clustering seen with the sec4-8 secretory vesicles correlated
with a loss of Sec4 function and not with an indirect defect in
the sec4-8 mutation on the functionality of the vesicles, we
made use of purified recombinant Rab GDI to extract Rab
GTPases from the vesicles. Secretory vesicle-enriched fractions
were generated from sec6-4, pretreated with GDP, and followed
by either extraction with recombinant Rab GDI or mock-
treated with buffer only before further purification on sorbitol



















































































FIGURE 2. Post-Golgi vesicles do not require functional SNARE proteins, Snc1/2 or Sso1/2, to cluster in vitro in the presence of Sro7, MgCl2, and GTPS.
A, sec6-4 mutant strain was shifted to the restrictive temperature of 37 °C to accumulate post-Golgi secretory vesicles and then spheroplasted, lysed, and
fractionated as described in Fig. 1 to obtain an HSP fraction enriched in labeled post-Golgi vesicles for the clustering assay. Vesicles depleted of the v-SNARE
Snc1/2 were generated by shifting a snc1;snc2 strain expressing GAL-SNC1 from YP  2% glucose into YP  3% raffinose for 14 h at room temperature before
processing as seen for the sec6-4 mutant strain. Vesicle amounts from the two strains were normalized by Western blot analysis of vesicle marker proteins (Sec4,
Snc1/2, and Sso1/2). Vesicle fractions were incubated with MgCl2 (3 mM) and GTPS (1 mM) for 30 min on ice and then treated with Sro7 (1 M) for 20 min at 27 °C
before analysis by fluorescence microscopy as described in Fig. 1. B, sec6-4 and a sso1;sso2-1 secretory mutant strain were grown at room temperature and
then shifted to 37 °C to accumulate post-Golgi vesicles. Strains were spheroplasted, lysed, and subjected to differential centrifugation to obtain an HSP fraction
enriched in vesicles that were normalized using Western blot analysis of vesicle marker proteins. The in vitro assay was then conducted and quantitated as
described in Fig. 1. Scale bar, 2 m.
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nearly 2⁄3 of the Sec4 from vesicles (Fig. 4C). The vesicles were
then used in the in vitro clustering assay with Sro7, magnesium
chloride, and GTPS. Although overall clustering was slightly
reduced following the more extensive incubations necessary
for GDI extraction (compare quantitation in Fig. 3B to 4B),
the observed clustering in the mock-treated vesicles was
dependent on Sro7. Importantly, the results shown in Fig. 4, A
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FIGURE 3. Purified post-Golgi vesicles cluster in vitro in the presence of Sro7, MgCl2, and GTPS. A, sec6-4 and sec4-8 mutant strains were shifted to the
restrictive temperature of 37 °C to accumulate secretory vesicles. Cells were then spheroplasted, lysed, and subjected to a 30,000  g spin to remove large
membranes. The lysates were then treated with FM4-64 and spun through a sorbitol cushion at 100,000  g to generate two HSP fractions that were then
subjected to parallel 20 – 40% sorbitol velocity gradients. Vesicle-containing fractions were collected from each gradient and subjected to a second 100,000 
g centrifugation to generate a homogeneous fraction of sec6-4 or sec4-8 vesicles. These were then treated with MgCl2 (3 mM) and GTPS (1 mM) for 30 min on
ice and then with Sro7 (1 M) for 60 min at 27 °C. Clustering was analyzed both by fluorescence microscopy (A) and negative stain electron microscopy (C). HSP
fractions of purified vesicles were monitored by Western blot analysis (B and D), and quantitation of vesicle clustering for A was based on counting 10 images
at 60 magnification and separating vesicle clusters by size. Scale bar, 2 m. Quantitation for C was based on counting three montages of nine frames each.
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results in a dramatic loss of the clustering potential of the purified
vesicles.
Rab GDI is known to have high specificity for Rab GTPases
(18); however, yeast post-Golgi vesicles are known to contain
several other Rab GTPases, including Ypt31 and Ypt1, which
could be responsible for the GDI-mediated inhibition in the
assay (19 –21). Therefore, to determine whether Sec4 is the rel-
evant Rab in this assay, we made use of a monoclonal antibody
specific to Sec4 (22) as a functional probe for Sec4 function in






























































































FIGURE 4. In vitro post-Golgi vesicle clustering depends on the presence of GTP-Sec4 on vesicles. A, HSP fraction obtained from a sec6-4 mutant strain was
treated with GDP (0.5 mM), MgCl2 (3.6 mM, and GDI (8 mM) or a mock buffer for 30 min on ice. The vesicles were then purified on parallel 20 – 40% sorbitol velocity
gradients. Vesicle-containing fractions from each column were subject to a second centrifugation to generate two concentrated vesicle fractions. GDI-treated
and mock-treated samples were then incubated with MgCl2 (3 mM) and GTPS (1 mM) on ice for 30 min and then with Sro7 (1 M) for 60 min at 27 °C. Results
of the clustering assay were analyzed by fluorescence microscopy (A), and quantitation of clustering is shown in B. Scale bar, 2 m. Vesicle amount used was
monitored by Western blot analysis (C) using polyclonal antibody to vesicle markers Sec4 and Snc1/2. D, HSP fraction obtained from a sec6-4 mutant strain was
incubated with equal amount of monoclonal anti-Sec4 or control monoclonal anti-Myc IgG for 1 h on ice before treating with MgCl2 (3 mM) and GTPS (1 mM)
for 30 additional min on ice. The vesicles were then incubated with Sro7 (1 M) for 20 min at 27 °C. The reaction was analyzed by fluorescence microscopy and
quantitated as described previously. Scale bar, 2 m.
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fraction with two different doses of either anti-Sec4 mAb or an
identical amount of a control mAb. Both antibodies were puri-
fied and used at identical concentrations in the assay by prein-
cubating them with vesicles for 1 h on ice prior to use in the
clustering assay. The results in Fig. 4D show that vesicles
treated with the anti-Sec4 monoclonal antibody, but not those
treated with the control antibody, demonstrated a pronounced
dose-dependent inhibition of clustering. Taken together with
the data obtained with sec4-8 vesicles and Rab GDI extraction
studies, this result provides strong evidence that Sec4 on the
surface of the post-Golgi vesicles is critical for Sro7-mediated
vesicle clustering.
Novel Mutant, Sro7-R189D,R222D, Fails to Cluster Post-
Golgi Vesicles in Vivo and in Vitro—To identify elements within
Sro7 that are important for vesicle tethering, we carried out a
small pilot screen of site-specific mutations in conserved sur-
face patches and examined their effect on Sro7-mediated vesi-
cle clustering in vivo and in vitro. Reverse charge mutagenesis
of four conserved surface “patches” of charged amino acids
resulted in four new mutants shown in Fig. 5A. All four mutants
were fully functional as the only copy of Sro7 in the cell when
expressed behind the endogenous Sro7 promoter (data not
shown). As a first attempt to determine whether any of these
mutants affect post-Golgi vesicle clustering, we introduced
each allele into a GAL1/10 expression plasmid and examined
the growth effects following induction on galactose-containing
media. As we have previously shown, GAL overexpression of
wild type SRO7 results in a significant growth defect in wild
type strains (4). Although three of the four charge reversal
mutants demonstrated pronounced growth defects, one of the
mutants, sro7-R189D,R222D (abbreviated as sro7-D189,D222),
did not cause cell lethality when overexpressed in wild type or a
more sensitive sec mutant strain, sec15-1, in which exocyst
function is compromised (Fig. 5B). To understand the biologi-
cal basis for the loss of growth inhibition, we determined the
effect of the expression of this allele on post-Golgi vesicle
clustering by immunofluorescence microscopy. As we have
observed previously, GAL induction of SRO7 results in large
puncta of Sec4- and Sro7-positive structures that correspond to
clusters of 80 –100-nm vesicles by thin section electron micros-
copy (Fig. 5C) (4). In contrast, when we induced expression of
sro7-D189,D222, no puncta were observed by either Sec4 or
Sro7 staining. Moreover, the normally highly polarized staining
of Sec4 appeared to be replaced often by a much more diffuse
staining pattern, although there is no effect on growth under
these conditions (Fig. 5C).
To compare the clustering activity of the sro7-D189,D222
mutant in vitro to the in vivo results described above, we puri-
fied the mutant protein to homogeneity and examined its abil-
ity to promote clustering in our assay. Although the mutant
protein shows no detectable effect on binding to GTP-Sec4
(Fig. 6B), it completely fails to stimulate vesicle clustering of
both FM4-64-labeled (Fig. 6A) or GFP-Sec4-labeled vesicles
(data not shown) isolated from sec6-4 strains. Furthermore, the
clustering defect cannot be ascribed to a defect in the interac-
tion with Myo2 (7) or Exo84 (3) because we find binding of the
purified Sro7-D189,D222 protein to recombinant forms of
Myo2 and Exo84 is indistinguishable from that of the wild type
Sro7 protein (Fig. 6C).
Examination of the arginine residues at positions 189 and 222
in the Sro7 crystal structure indicates that these residues, which
lie on the surface of the N-terminal -propeller, play an impor-
tant role in the interaction with the C-terminal autoinhibitory
tail (Fig. 5A). The autoinhibitory tail is thought to regulate
interaction of Sro7 with the Qbc-SNARE domain of the plasma
membrane t-SNARE, Sec9 (5). To test the idea that the effect of
the Asp-189 and Asp-222 mutations on clustering is through
loss of the autoinhibitory interaction of the C-terminal domain
with the propeller, we generated an additional set of mutations
(N914K and S942F) in the C-terminal tail, which form strong
hydrogen bond interactions with the two arginine residues on
the N-terminal propeller (Fig. 7A). To test the structural predic-
tion that the autoinhibitory tail would be in a more “open” confor-
mation in both the Sro7-D189,D222 and Sro7-K914,F942 mutant
proteins, we examined their ability to bind the Sec9-Qbc domain
fused to GST. The results, shown in Fig. 7B, demonstrate that both
of these mutant proteins show significantly improved binding to
GST-Sec9Qbc compared with equivalent quantities of wild type
Sro7.
To determine whether the sro7-K914,F942 mutant, like the
sro7-D189,D222 mutant, suppresses the vesicle clustering phe-
notype in vivo, we expressed this mutant behind the GAL pro-
moter. The results in Fig. 7C show that this new allele, like the
sro7-D189,D222, prevents the galactose-dependent inhibition
of growth. Importantly, we also find that GAL induction of this
allele prevents formation of the large Sec4 positive vesicle clus-
ters seen with wild type Sro7 (Fig. 7D). Finally, we determined
whether the purified Sro7-K914,F942 protein had reduced
activity in the in vitro vesicle clustering assay by comparing it
with the wild type Sro7 and the Sro7-D189,D222 mutant. The
results in Fig. 8A demonstrate that the two mutant forms of
Sro7 are completely inactive for in vitro vesicle clustering,
despite the fact they show normal binding to Myo2, Exo84, and
enhanced binding to Sec9-Qbc.
These data strongly suggest that the closed form of Sro7,
where the C-terminal autoinhibitory tail is engaged with the
N-terminal propeller, is most active in Rab-dependent vesicle
clustering. Because the closed conformation is mutually exclu-
sive with binding of the Sec9-Qbc domain to Sro7, we asked
whether prebinding of Sro7 to excess full-length Sec9 protein
would affect the clustering activity of otherwise wild type Sro7.
The results of this experiment, shown in Fig. 8B, demonstrate
that binding of Sec9 to Sro7 in the assay potently inhibited
vesicle clustering by Sro7, exactly as predicted by this model.
The inhibition by Sec9 is dose-dependent (Fig. 8D) and specific
in that neither the cytoplasmic domain of Sso1 nor Snc1
showed any effect in the assay (Fig. 8, B and C). Also consistent
with the notion that Sec9 inhibition is through binding to Sro7,
we find that eliminating the prebinding incubation step signif-
icantly reduced the inhibitory effect of Sec9 on Sro7-mediated
clustering (data not shown). Taken together, we find that
“opening” the autoinhibitory tail by three different means, pro-
peller mutant, tail mutants, or Sec9 binding, all lead to inhibi-
tion of clustering activity. This suggests that the binding of the
autoinhibitory tail acts as a “switch” to coordinate Sro7 function in
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Rab-dependent membrane tethering and SNARE assembly.
Although the precise order of events necessary to turn this switch
will need to be sorted out, one attractive model would be that
closure of the autoinhibitory tail would act to temporally regulate
Rab-mediated vesicle tethering with SNARE assembly necessary
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FIGURE 5. Novel mutant of Sro7, sro7-R189D,R222D fails to induce clustering and cell lethality in vivo. A, schematic and surface-filling model show the
four new, surface-exposed, conserved charge-reversal Sro7 mutants as follows: red, Sro7-R189D,R222D; yellow, Sro7-K196E,R210D; light blue, Sro7-
K794E,H797E,K798E; violet, Sro7-K576E. B, wild type and sec15-1 mutant strains were transformed with plasmids, (CEN) overexpressing Sro7, or the charge
reversal mutants from a GAL promoter. Three individual colonies were picked and transferred to selective media in the presence of glucose or galactose. Equal
absorbance units of the strains induced in galactose were harvested, washed in Tris (10 mM) and azide (20 mM), and lysed by glass bead lysis before subjecting
to Western blot analysis. C, wild type cells containing plasmids expressing SRO7 or sro7-D189,D222 from a GAL-inducible promoter (CEN) or vector only were
grown in selective media and induced for 6 h in galactose before fixing and processing for immunofluorescence analysis using monoclonal Sec4 and polyclonal
Sro7 antibodies. Scale bar, 2 m.
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DISCUSSION
In this paper, we describe for the first time an in vitro
system in which we recapitulate Rab-dependent post-Golgi
vesicle/vesicle clustering induced by the yeast Lgl/tomosyn
family member Sro7. We find that many of the features pres-
ent in Sro7-mediated vesicle clustering in vivo and in vitro
closely resemble vesicle tethering events that are thought to
occur prior to fusion with the target membrane. The most
important similarity is the requirement in both cases for
GTP-bound Rab protein and a direct Rab effector in the
formation of a close physical apposition of a vesicle with an
opposing membrane. It has been previously suggested that
this phenomenon might involve symmetric “pairing” of Rab-
GTP molecules on both membranes, which may be stabilized
by effector/Rab and effector/effector interactions (23). Cer-
tainly the dependence of the clustering assay and post-Golgi
transport on Sec4-GTP and Sro7 supports this notion,
although further biochemical dissection of this system will
be required to distinguish the precise tethering mechanism
involved.
Genetically and biochemically, Sro7 has features that sug-
gest it likely functions parallel to the exocyst complex down-
stream of the Sec4 GTPase. Evidence for a parallel function



































































































































FIGURE 6. Biochemical characterization of Sro7-D189,D222 shows that although the novel mutant cannot cluster vesicles in the in vitro clustering
assay, it can still bind to Sec4-GTP, Myo2, and Exo84 in GST pulldown assays. A, Sro7 and Sro7-D189,D222 were purified and analyzed at identical
concentrations in the in vitro clustering assay. Scale bar, 2 m. B, purified Sro7 and Sro7-D189,D222 also examined for binding to GST fusions of the Rab GTPase
Sec4; C, IQ region of Myo2 (amino acids 782–990) and the N terminus of Exo84 (amino acids 3– 400) by standard methods described previously. Percent binding
in C was expressed using wild type Sro7 binding as 100%. All bindings represent the result of three independent experiments conducted with two different
concentrations of GST fusion proteins on beads.
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binding to Sec4 (like the Sec15 component) and dosage sup-
pression of a number of exocyst mutants, including bypass
suppression of exo70, sec5, and sec3 (1, 2). However,
because Sro7 also physically interacts with the Exo84 com-
ponent of the exocyst complex, some aspects of its activity
may be interdependent with the exocyst (3). In the assay
described in this paper, it is clear that the tethering/cluster-
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FIGURE 7. Sro7-N914K,S942F behaves genetically and biochemically like sro7-R189D,R222D. A, schematic structure of Sro7 illustrating hydrogen bonds
between R189,R222 on the N-terminal propeller of Sro7 and N914,S942 on the C-terminal tail. B, wild type and mutant Sro7 proteins were purified and analyzed
for binding to the Sec9-Qbc domain as described previously. Standard Student’s t test showed a p value of 	0.001. C, wild type and sec15-1 mutant strains were
transformed with plasmids (CEN) overexpressing SRO7, sro7-D189,D222 and sro7-K914,F942 from a GAL promoter. Three individual colonies were picked and
transferred to selective media in the presence of glucose or galactose. Equal absorbance units of the strains induced in galactose were harvested, washed in Tris
(10 mM) and azide (20 mM), and lysed by glass bead lysis before subjecting to Western blot analysis. D, wild type cells containing plasmids expressing Sro7, or
mutant proteins from a GAL-inducible promoter (CEN), or vector only were grown in selective media and induced for 6 h in galactose before fixing and
processing for immunofluorescence analysis using monoclonal Sec4 and polyclonal Sro7 antibodies. Scale bar, 2 m.
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of the exocyst, as this complex does not stably associate with vesi-
cles and is absent from post-Golgi vesicles following the size-de-
pendent purification method used in this work (24).
Previous structural analyses of the Rab effector Sro7 (5)
strongly suggest that binding of the C-terminal autoinhibitory
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FIGURE 8. Sro7 mutants that favor an open conformation inhibit Sro7-mediated vesicle clustering in vitro. A, Sro7, Sro7-D189,D222 and Sro7-K914,F942
were purified and analyzed at identical concentrations in the in vitro clustering assay. Scale bar, 2 m. B, in vitro clustering assay was performed with Sro7 (1.5
M) or a mixture of Sro7 and Sec9 (1:1), Sro7 and GST-Snc (1:1), Sro7 and GST-Sso1 (1:1), or GST-Sso1 (amino acids 193– 651) (1:1) previously incubated on ice
for 60 min. The assay was analyzed and quantitated as described previously. Results of the quantitation and Coomassie stain of the proteins used is shown in
C. D, inhibitory effect of Sec9 on Sro7 is dose-dependent. E, model showing how the closed conformation of Sro7 allows release of the Sec9-Qbc domain and
Rab-dependent vesicle clustering to occur simultaneously.
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switch in the function of this protein in vesicle transport. In this
model, Sro7 would deliver the t-SNARE Sec9 to sites of fusion
with the Sec9-Qbc domain bound to the N-terminal propeller
and the autoinhibitory domain in the “open” conformation (see
Fig. 8E). When the appropriate signal or trigger is present, the
autoinhibitory domain would bind back to the N-terminal pro-
peller, resulting in the release of the Sec9-Qbc domain. This
would then allow the Sec9-Qbc domain to be available for
assembly into active t-SNARE and trans-SNARE complexes
required for vesicle fusion. Here, using two sets of point mutations
shown to destabilize the autoinhibitory tail, we demonstrate that
the conformational status of the tail plays a critical role in deter-
mining the activity of Sro7 in Sec4-dependent vesicle clustering.
Although both regulation of the tail of Sro7 and the presence of
Sec4-GTP are important for clustering in vitro and in vivo, Sec4
binding by itself does not appear to be the trigger for this confor-
mational switch, because mutations that favor the open conforma-
tion show equivalent binding to Sec4-GTP.
Because Rab-dependent vesicle tethering to the appropriate
membrane is thought to occur prior to the SNARE-mediated
fusion, we expected that the open conformation of Sro7 would
be most active in Rab-GTP-mediated vesicle clustering. The
fact that we find exactly the opposite of this expectation, i.e. the
open conformation is inactive, may be indicative of a quite dif-
ferent temporal relationship between Rab tethering and fusion.
Instead of happening at quite discrete and sequential stages,
these two events appear to be coincident in their regulation.
This may help to ensure that neither Rab-mediated tethering nor
SNARE-mediated fusion occur promiscuously with the wrong
membrane by requiring an additional triggering interaction. We
have previously described another “gating” interaction with the
type V myosin Myo2, by which the interaction between Sro7 and
Sec4 is regulated. Taken together, this suggests that Sro7 is well
designed to orchestrate assembly and disassembly events on the
surface of the post-Golgi vesicles that are critical for vesicle trans-
port, tethering, and fusion. This may help to aid in increasing the
overall spatial and temporal specificity of the transport events.
The development of the in vitro assay described here will be
an important tool for further dissecting the mechanism by
which Rab GTPases and their effectors function in transport.
Further identification of protein/protein and protein/lipid
interactions that are important for post-Golgi transport in vivo
and vesicle clustering in vitro will allow specific models for the
role of Sro7 in these processes to be tested.
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